Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Lymphoma 8Lymphoma, T-Cell, Cutaneous 6Leukemia, Lymphocytic, Chronic, B-Cell 6Melanoma 5Lymphoma, T-Cell, Peripheral 5Carcinoma, Ovarian Epithelial 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Follicular 4Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Fallopian Tube Neoplasms 3Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Kidney Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Turcot syndrome 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1

Interventions

Amifostine 19Cisplatin 15Radiotherapy 13Etoposide 10Cyclophosphamide 9Carboplatin 8Paclitaxel 7Filgrastim 7Drug Therapy 5Cytarabine 5apatinib 4Methotrexate 4sodium thiosulfate 3Methylprednisolone 3Gemcitabine 3Docetaxel 3sargramostim 2pegfilgrastim 2glucarpidase 2etoposide phosphate 2denileukin diftitox 2camrelizumab 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mitoxantrone 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × denileukin diftitox × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

NCT00006345 2013-05-30

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡